-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT ANNOUNCES PHASE 3 RESTORE-3 STUDY OF SYCUME® (TEPROTUMUMAB N01 INJECTION) MET PRIMARY ENDPOINT IN INACTIVE THYROID EYE DISEASE

Reuters·10/09/2026 00:00:00

Please log in to view news